Abbott cuts its 2026 full year sales growth view

Abbott Laboratories reduced its 2026 sales growth forecast to 6% from 6.5-7.5%, citing challenges in its nutrition business, including lost contracts and higher costs. The company plans to spin off its nutrition division, which includes Similac, by the end of 2027. Q3 sales were $13.01B, missing estimates, while adjusted EPS met expectations at $1.42. The 2026 adjusted EPS forecast was tightened to $5.50-$5.55.

Original reporting
Published Oct 21, 2026, 1:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Abbott cuts its 2026 full year sales growth view — source image
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The guidance cut and spin‑off announcement are fresh disclosures that could reshape investor expectations for both the parent and the future nutrition spin‑off.

02

Market read

First‑report of a material guidance downgrade and corporate restructuring for a large‑cap US healthcare stock, likely moving the stock in the near term.

03

What to watch

Potential cost synergies from the separation and possible strategic partnerships for the new nutrition entity are not reflected in the initial reaction.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Abbott is a diversified healthcare company with medical devices, diagnostics, pharmaceuticals and nutrition products. The nutrition segment has faced supply‑contract loss, higher costs and litigation.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott announced a cut to its 2026 sales growth forecast to about 6% and a plan to spin off its nutrition business into a separate public company by end‑2027.

Expected impact

likely downside as investors price in slower growth and uncertainty around the separation.

Evidence & confidence

The new guidance is the first public disclosure and materially below prior expectations; spin‑off adds execution risk.

Market effects

Healthcare sector may see modest pressure as a large diversified player signals slower growth, while nutrition niche could attract interest.

U.S. large‑cap healthcare index may dip slightly on the news.

Limited to investors tracking major US healthcare stocks; no broader macro impact.

Counterpoint

The spin‑off could unlock value in the nutrition unit, offering a buying opportunity if the market overreacts to the growth cut.

Key entities

  • Abbott Laboratories

    US‑listed healthcare conglomerate (ticker ABT).

  • Robert Ford

    CEO of Abbott who announced the separation.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.